Stock listing
NASDAQ:AZR Azora Therapeutics, Inc. Stock
Follow Azora Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AZR
$3.85 USD +0.05 (+1.3%)
Close on Nov 20, 2026
- Day range
- $3.56 – $3.90 USDNov 20, 2026
- Volume
- 41,824 sharesNov 20, 2026
- Market cap
- $55.00M USDAt the close on Nov 20, 2026 · price × 14.29M shares outstanding
- 52-week range
- $1.31 – $8.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $230,200 USDMedian day 43,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AZR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.85 | +0.05 | +1.3% | $3.75 | $3.90 | $3.56 | 41,824 | |
| $3.80 | +0.135 | +3.7% | $3.56 | $3.96 | $3.45 | 208,735 | |
| $3.665 | -0.145 | -3.8% | $3.63 | $3.95 | $3.47 | 43,290 | |
| $3.81 | -0.28 | -6.8% | $3.78 | $3.945 | $3.58 | 8,037 | |
| $4.09 | +0.35 | +9.4% | $3.77 | $4.09 | $3.76 | 10,965 | |
| $3.74 | +0.23 | +6.6% | $3.59 | $4.035 | $3.428 | 50,812 | |
| $3.51 | -0.25 | -6.6% | $3.75 | $3.87 | $3.45 | 11,011 | |
| $3.76 | +0.01 | +0.3% | $3.75 | $3.987 | $3.74 | 83,518 | |
| $3.75 | -0.25 | -6.3% | $4.03 | $4.30 | $3.74 | 31,418 | |
| $4.00 | +0.29 | +7.8% | $3.91 | $4.00 | $3.755 | 78,187 | |
| $3.71 | -0.34 | -8.4% | $4.04 | $4.04 | $3.71 | 18,500 | |
| $4.05 | -0.10 | -2.4% | $3.95 | $4.30 | $3.95 | 7,000 | |
| $4.15 | +0.26 | +6.7% | $4.07 | $4.39 | $3.68 | 33,100 | |
| $3.89 | +0.08 | +2.1% | $4.70 | $4.83 | $3.80 | 43,400 | |
| $3.81 | -1.07 | -21.9% | $4.71 | $4.94 | $3.02 | 169,200 | |
| $4.88 | -0.17 | -3.4% | $4.50 | $4.97 | $3.67 | 146,900 | |
| $5.05 | +1.34 | +36.1% | $3.98 | $5.15 | $3.80 | 99,700 | |
| $3.71 | +0.03 | +0.8% | $3.72 | $3.98 | $3.67 | 7,400 | |
| $3.68 | -0.24 | -6.1% | $3.94 | $3.94 | $3.59 | 11,700 | |
| $3.92 | -0.30 | -7.1% | $4.15 | $4.28 | $3.92 | 47,400 | |
| $4.22 | +0.11 | +2.7% | $4.16 | $4.22 | $4.16 | 2,300 | |
| $4.11 | +0.29 | +7.6% | $3.75 | $4.41 | $3.75 | 21,500 | |
| $3.82 | +0.20 | +5.5% | $3.51 | $3.98 | $3.51 | 8,400 | |
| $3.62 | +0.13 | +3.7% | $3.54 | $3.66 | $3.46 | 12,100 | |
| $3.49 | +0.35 | +11.1% | $3.07 | $3.66 | $3.07 | 56,400 | |
| $3.14 | +0.14 | +4.7% | $3.00 | $3.30 | $3.00 | 13,900 | |
| $3.00 | -0.29 | -8.8% | $3.17 | $3.32 | $3.00 | 27,400 | |
| $3.29 | -0.21 | -6.0% | $3.52 | $3.87 | $3.20 | 75,400 | |
| $3.50 | -0.40 | -10.3% | $4.04 | $4.04 | $3.47 | 167,000 | |
| $3.90 | -0.07 | -1.8% | $4.03 | $4.06 | $3.90 | 3,000 | |
| $3.97 | -0.02 | -0.5% | $4.02 | $4.05 | $3.92 | 4,900 | |
| $3.99 | +0.01 | +0.3% | $3.91 | $4.09 | $3.91 | 4,400 | |
| $3.98 | -0.37 | -8.5% | $4.38 | $4.50 | $3.98 | 11,900 | |
| $4.35 | +0.23 | +5.6% | $4.05 | $4.43 | $3.92 | 60,000 | |
| $4.12 | -0.01 | -0.2% | $4.13 | $4.66 | $3.92 | 64,500 | |
| $4.13 | +0.12 | +3.0% | $4.12 | $4.45 | $3.86 | 13,400 | |
| $4.01 | -0.14 | -3.4% | $4.16 | $4.29 | $3.95 | 35,300 | |
| $4.15 | +0.11 | +2.7% | $4.04 | $4.30 | $3.97 | 29,300 | |
| $4.04 | -0.18 | -4.3% | $4.05 | $4.30 | $3.85 | 47,500 | |
| $4.22 | -0.22 | -5.0% | $4.40 | $4.56 | $4.12 | 33,200 | |
| $4.44 | +0.40 | +9.9% | $4.00 | $4.64 | $4.00 | 47,300 | |
| $4.04 | -0.16 | -3.8% | $4.25 | $4.25 | $3.77 | 60,900 | |
| $4.20 | -0.20 | -4.5% | $4.40 | $4.42 | $4.14 | 40,200 | |
| $4.40 | -0.46 | -9.5% | $4.82 | $4.82 | $4.23 | 43,700 | |
| $4.86 | -0.35 | -6.7% | $5.23 | $5.23 | $4.59 | 86,900 | |
| $5.21 | -0.03 | -0.6% | $5.25 | $5.38 | $5.04 | 21,600 | |
| $5.24 | +0.24 | +4.8% | $5.01 | $5.30 | $5.00 | 29,700 | |
| $5.00 | 0.00 | 0.0% | $5.02 | $5.18 | $4.80 | 29,000 | |
| $5.00 | +0.10 | +2.0% | $4.94 | $5.18 | $4.87 | 46,500 | |
| $4.90 | -1.10 | -18.3% | $6.06 | $6.11 | $4.80 | 108,500 | |
| $6.00 | +0.07 | +1.2% | $5.94 | $6.22 | $5.90 | 17,200 | |
| $5.93 | -0.72 | -10.8% | $6.64 | $6.65 | $5.87 | 48,700 | |
| $6.65 | -0.47 | -6.6% | $7.01 | $7.20 | $6.33 | 67,600 | |
| $7.12 | +0.46 | +6.9% | $6.61 | $7.20 | $6.27 | 50,100 | |
| $6.66 | +0.34 | +5.4% | $6.32 | $6.80 | $6.25 | 52,800 | |
| $6.32 | +0.37 | +6.2% | $5.92 | $6.43 | $5.80 | 53,800 | |
| $5.95 | +0.20 | +3.5% | $5.80 | $6.17 | $5.51 | 44,400 | |
| $5.75 | +0.15 | +2.7% | $5.57 | $5.98 | $5.30 | 69,900 | |
| $5.60 | -0.09 | -1.6% | $5.70 | $5.79 | $5.45 | 63,500 | |
| $5.69 | -0.25 | -4.2% | $5.96 | $5.96 | $5.45 | 53,600 | |
| $5.94 | +0.12 | +2.1% | $5.84 | $6.07 | $5.59 | 64,600 | |
| $5.82 | +0.42 | +7.8% | $5.35 | $5.90 | $5.19 | 32,100 | |
| $5.40 | -0.82 | -13.2% | $6.19 | $6.19 | $4.70 | 132,300 | |
| $6.22 | +0.32 | +5.4% | $5.95 | $6.41 | $5.74 | 81,700 | |
| $5.90 | +0.14 | +2.4% | $5.81 | $5.94 | $5.36 | 42,000 |
Splits
2 splits since 2023 · NASDAQ:AZR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:AZR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 22 slides
Latest news
Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Nov 19, 2026
Closed $3.85 (+1.3%) on Nov 20, 2026
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Nov 12, 2026
Closed $4.09 (+9.4%) on Nov 13, 2026
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Nov 5, 2026
Closed $3.71 (-8.4%) on Nov 5, 2026
Azora Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Nov 19, 2026 · oldest 2026
- Decks
- 1 deck · latest October 2026
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $33.00M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.00
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.36M | n/a | 373× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.77M | US$51.65M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| EyeGene, Inc. · KRX:185490 | US$55.57M | US$26.66M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Median of the others | US$55.28M | US$31.11M | 39.2× | 1.8× | −132.6% | 0.0× | 1.65 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.94 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Matt Davidson | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Kevin Schuyler | Chairman of the Board |
| J. Kermit Anderson | Director |
| Matt Davidson | Chief Executive Officer |
| Robertson Gilliland | Director |
| Wendy Young | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +9.4% |
| Q2 2026 | Aug 19, 2026 | +8.3% |
| Q1 2026 | May 11, 2026 | −3.5% |
| Q4 2025 | Mar 9, 2026 | 0.0% |
| Q3 2025 | Nov 14, 2025 | −3.1% |
| Q2 2025 | Aug 13, 2025 | −2.5% |
| Q1 2025 | May 15, 2025 | +1.5% |
| Q4 2024 | Mar 4, 2025 | +5.5% |
| Q3 2024 | Nov 13, 2024 | +11.8% |
| Q2 2024 | Aug 19, 2024 | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 | −12.1% |
| Q4 2023 | Mar 28, 2024 | −12.1% |
| Q3 2023 | Nov 14, 2023 | +5.5% |
| Q2 2023 | Aug 21, 2023 | −3.5% |
| Q1 2023 | May 12, 2023 | 0.0% |
| Q3 2022 | Nov 14, 2022 | +3.6% |
| Q2 2022 | Aug 16, 2022 | −5.0% |
| Q1 2022 | May 16, 2022 | +15.6% |
| Q4 2021 | Mar 2, 2022 | −3.5% |
| Quarter to Sep 30, 2021 | Nov 16, 2021 | +4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 22 slides | October 2026 |
IPO
Went public as ADIAL PHARMACEUTICALS, INC. Priced at US$5.00 a unit on Jul 26, 2018.
- Price
- US$5.00 a unit
- Units offered
- 1,464,000 units
- Offering size
- US$7.3 million
- Underwriters' option
- Up to 219,600 more units
- Listing
- ADIL on the Nasdaq Capital Market
- Underwriters
- Joseph Gunnar & Co., Dawson James Securities, Inc. · In the order on the cover
- Units delivered
- On or about Jul 31, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 12, 2017 |
| Filed publicly | Sep 7, 2017 |
| Amended 8 times | Newest Jul 10, 2018 |
| Shares registered with an exchange | Dec 11, 2017 |
| Declared effective by the SEC | Jul 26, 2018 |
| Final prospectus, with the price | Jul 30, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2018 |
| CERT · Exchange's certificate of listing | Jul 27, 2018 |
| EFFECT · Notice that a registration is effective | Jul 26, 2018 |
| EFFECT · Notice that a registration is effective | Jul 26, 2018 |
| CORRESP · Letter to the SEC | Jul 24, 2018 |
| CORRESP · Letter to the SEC | Jul 24, 2018 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Jul 23, 2018 |
| FWP · Free writing prospectus | Jul 10, 2018 |
| S-1/A · Registration statement, amended | Jul 10, 2018 |
| UPLOAD · Letter from the SEC | Jul 3, 2018 |
All 41 filings
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | |||||
| Research and development | 2.62M | 3.23M | 1.27M | 1.95M | 8.40M | 5.85M | 3.97M | 368.5K | 182.1K |
| Selling, general and administrative | 5.18M | 5.06M | 5.62M | 8.91M | |||||
| Operating income | -7.80M | -8.28M | -6.89M | -10.9M | -19.3M | -10.9M | -8.24M | -6.99M | -995.3K |
| Depreciation and amortization | 565 | 565 | 564 | 564 | |||||
| EBITDA | -7.80M | -8.28M | -6.89M | -10.9M | |||||
| Income before tax | -7.98M | -13.2M | -7.00M | -10.8M | -19.5M | -10.9M | -8.59M | -11.6M | -1.14M |
| Income tax | -502 | -94.1K | |||||||
| Net income | -7.98M | -13.2M | -5.12M | -12.7M | -19.4M | -10.9M | -8.59M | -11.6M | -1.14M |
| Earnings per share, basic | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 |
| Earnings per share, diluted | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M | 4.40M | 6.78M | 3.87M | 18.2K |
| Receivables | 41.8K | ||||||||
| Current assets | 6.18M | 4.06M | 3.20M | 4.78M | 6.46M | 5.14M | 7.67M | 4.69M | 27.2K |
| Property, plant and equipment | 50.4K | 58.1K | |||||||
| Goodwill | 249.0K | 249.0K | |||||||
| Total assets | 6.67M | 5.04M | 4.74M | 5.73M | 7.47M | 5.49M | 7.68M | 4.70M | 34.5K |
| Accounts payable | 655.0K | 250.1K | 103.3K | 276.4K | 286.2K | 648.7K | 190.2K | 99.7K | |
| Current liabilities | 1.40M | 975.9K | 653.1K | 1.79M | 2.72M | 1.51M | 539.1K | 258.0K | 1.03M |
| Total liabilities | 1.40M | 975.9K | 653.1K | 2.46M | 3.97M | 1.51M | |||
| Shareholders' equity | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M | 3.99M | 7.14M | 4.44M | -997.6K |
| Shares outstanding | 1.11M | 258.8K | 1.66M | 1.07M | 20.9M | 14.4M | 10.4M | 6.86M | 3.27M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.49M | -6.92M | -6.81M | -11.2M | -11.9M | -7.63M | -6.34M | -2.50M | -494.9K |
| Capital spending | 0 | 0 | 0 | 0 | -64.6K | ||||
| Free cash flow | -6.49M | -6.92M | -6.81M | -11.2M | -12.0M | ||||
| Cash from investing | 150.0K | 1.50M | -34.0K | -350.0K | 35.1K | ||||
| Cash from financing | 8.47M | 7.85M | 4.13M | 9.13M | 13.6M | 5.61M | 9.25M | 6.35M | 390.0K |
| Share buybacks | -1.66K | ||||||||
| Change in cash | 2.13M | 923.4K | -1.17M | -2.06M | 1.66M | -2.38M | 2.91M | 3.85M | -69.7K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Nov 16, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Nov 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Oct 27, 2026 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | Oct 20, 2026 | Quarterly report | SEC |
| S-3/A · Registration statement, amended | Oct 20, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Oct 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Sep 18, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 18, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Sep 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Material contract | SEC |
| S-3 · Registration statement | Aug 28, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 28, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 25, 2026 | Financing | SEC |
| ARS · Annual report to shareholders | Aug 24, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 8-K · Current report | Aug 17, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Aug 10, 2026 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Aug 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2026 | Results | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2026 | Current report | SEC |
| 8-K · Current report | Jan 6, 2026 | Management or board change | SEC |
| DEF 14A · Proxy statement | Jan 6, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2025 | Meeting notice | SEC |
| 424B5 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 18, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 15, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 12, 2025 | Offer document | SEC |
| D | Dec 3, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 1, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 9, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 1, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 1, 2025 | Management or board change | SEC |
| 424B5 · Prospectus | Jul 31, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 16, 2025 | Current report | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| DEFR14A | Jun 27, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 18, 2025 | Offer document | SEC |
| PRER14A | Jun 17, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jun 17, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Jun 13, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 12, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Jun 10, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 10, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Jun 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 6, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 6, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 5, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| S-3 · Registration statement | May 30, 2025 | Offer document | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2025 | Current report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| D | May 13, 2025 | Other filings | SEC |
| 8-K · Current report | May 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | May 2, 2025 | Offer document | SEC |
| 424B5 · Prospectus | May 2, 2025 | Offer document | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Mar 27, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Mar 27, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 21, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 7, 2025 | Current report | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 31, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 31, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 26, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 20, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 18, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Dec 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 6, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Sep 27, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 27, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 26, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 23, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 22, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Apr 18, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 18, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 17, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 16, 2024 | Management or board change | SEC |
| S-3 · Registration statement | Apr 12, 2024 | Offer document | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| D | Mar 14, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 6, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jan 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 19, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 18, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 16, 2024 | Meeting outcome | SEC |
| S-3 · Registration statement | Jan 12, 2024 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 14, 2023 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Dec 12, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Dec 8, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 8-K · Current report | Nov 28, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Nov 24, 2023 | Meeting notice | SEC |
| 424B3 · Prospectus | Nov 20, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 15, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2023 | Other filings | SEC |
| S-1 · Registration statement | Nov 8, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2023 | Management or board change | SEC |
| 10-Q/A · Quarterly report, amended | Oct 30, 2023 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Oct 30, 2023 | Acquisition or disposal | SEC |
| NT 10-Q/A · Late filing notice, amended | Oct 30, 2023 | Explanation request | SEC |
| D | Oct 26, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 24, 2023 | Material contract | SEC |
This page holds 200 of 583 filings. Open Filings
Cap table
Built by 6ix from Azora Therapeutics, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 14,286,312
- Fully diluted
- 14,326,312
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 14,286,312 | |
| Options and RSUs | 40,000 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$3.81 · expire about Nov 2036 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 14,286,312 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cary Claiborne Other companies: Adial Pharmaceuticals, Inc (Chief Executive Officer, Director · Since at least Apr 7, 2026); NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026) | Chief Executive Officer, Director · Since at least May 29, 2025 |
| Robertson Gilliland Other companies: Adial Pharmaceuticals, Inc (Director · Since at least Apr 7, 2026) | Director · Since at least May 23, 2023 |
| Bankole A Johnson | Director · Jul 26, 2018 – May 23, 2023 · Past |
| James W Newman Jr | Director · Since at least Jul 26, 2018 |
| J. Kermit Anderson | Director · Since at least May 29, 2025 |
| Joseph Truluck | Chief Financial Officer · Jul 26, 2018 – Mar 25, 2024 · Past |
| Julie Saiki | Chief Strategy Officer · Since at least Nov 2, 2026 |
| Kevin Schuyler | Chairman of the Board · Since at least Nov 5, 2026 |
| Matt Davidson | Chief Executive Officer · Since at least Nov 4, 2026 |
| Wendy Young | Independent Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Azora Therapeutics, Inc.